Exfoliative Dermatitis Medication
- Author: David Vearrier, MD, MPH; Chief Editor: Barry E Brenner, MD, PhD, FACEP more...
Treatment of the underlying illness is key since exfoliative dermatitis resists treatment until the basic disease is treated. Cyclosporine has been reported to be effective, as has etanercept.
These agents have anti-inflammatory properties and cause profound and varied metabolic effects. They modify the body's immune response to diverse stimuli. They also are used to treat idiopathic and acquired autoimmune disorders.
Prednisone is a glucocorticoid that readily is absorbed from the GI tract. It is used primarily for anti-inflammatory effects in disorders of many organ systems.
These agents are used to treat minor allergic reactions and anaphylaxis. They are used for relief of pruritus.
Diphenhydramine is for symptomatic relief of symptoms caused by the release of histamine in allergic reactions. It may control itching by blocking the effects of endogenously released histamine.
These agents interfere in the immune processes that promote inflammation. They are used to relieve chronic severe dermatitis.
Cyclosporine has been demonstrated to cause remission in some patients. It has improved the overall prognosis of exfoliative dermatitis.
Antirheumatic, Disease Modifying
These agents modulate inflammatory and immune responses.
Etanercept is a soluble p75 TNF receptor fusion protein (sTNFR-Ig). It inhibits TNF binding to cell surface receptors, which, in turn, decreases inflammatory and immune responses. It has been reported to be effective. There is no current FDA approval/indication for the use of this drug with exfoliative dermatitis.
Sterry W, Steinhoff M. Erythroderma. Bolognia JL, Jorizzo JL, Schaffer JV, eds. Dermatology. 3rd ed. Elsevier Limited; 2012. 171-81.
Salami TA, Enahoro Oziegbe O, Omeife H. Exfoliative dermatitis: patterns of clinical presentation in a tropical rural and suburban dermatology practice in Nigeria. Int J Dermatol. 2012 Sep. 51(9):1086-9. [Medline].
Kanthraj GR, Srinivas CR, Devi PU, Ganasoundari A, Shenoi SD, Deshmukh RP, et al. Quantitative estimation and recommendations for supplementation of protein lost through scaling in exfoliative dermatitis. Int J Dermatol. 1999 Feb. 38 (2):91-5. [Medline].
Mahajan VK, Singh R, Mehta KS, Chauhan PS, Sharma S, Gupta M, et al. Idiopathic hypereosinophilic syndrome: a rare cause of erythroderma. J Dermatol Case Rep. 2014 Dec 31. 8 (4):108-14. [Medline].
Bolognia JL, Schaffer JV, Duncan KO, Ko CJ. Erythroderma. Dermatology Essentials. Philadelphia, Pa: Elsevier Saunders; 2014. 76-83.
Zhang JC, Sun YT. Efavirenz-induced exfoliative dermatitis. Scand J Infect Dis. 2012 Jun 20. [Medline].
Ipek Y, Hulya D, Melih A. Disseminated exfoliative dermatitis associated with all-transretinoic Acid in the treatment of acute promyelocytic leukemia. Case Report Med. 2012. 2012:236174. [Medline]. [Full Text].
Brănişteanu DE, Voicu CM, Creţu A, Dimitriu A, Luca MC, Sălăvăstru CM. Adverse reactions of biological therapy for psoriasis. Rev Med Chir Soc Med Nat Iasi. 2015 Jan-Mar. 119 (1):38-44. [Medline].
Shim TN, Berth-Jones J. Erythroderma. Lebwohl MG, Heymann WR, Berth-Jones J, Coulson I, eds. Treatment of Skin Disease: Comprehensive Therapeutic Strategies. 4th ed. Philadelphia, Pa: Elsevier Saunders; 2013. 234-38.
Sommer S, Henderson CA. Papuloerythroderma of Ofuji responding to treatment with cyclosporin. Clin Exp Dermatol. 2000 Jun. 25(4):293-5. [Medline].
Querfeld C, Guitart J, Kuzel TM, Rosen S. Successful treatment of recalcitrant, erythroderma-associated pruritus with etanercept. Arch Dermatol. 2004 Dec. 140(12):1539-40. [Medline].
|Atopic dermatitis (common)|
|Drug reactions (common)|
|Cutaneous T-cell lymphoma|
|Pityriasis rubra pilaris |
|Contact and stasis dermatitis with autosensitization|
|Paraneoplastic erythroderma |